Sun Pharmaceutical Industries Limited ((IN:SUNPHARMA)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Sun Pharmaceutical Industries Limited is conducting a significant clinical study titled ‘Randomized, Multi-Center, Evaluator-Blind, Vehicle-Controlled Study to Evaluate Efficacy and Safety of Reformulated Levulan Kerastick Plus Photodynamic Therapy (PDT) for Field-Directed Treatment in Patients With Actinic Keratosis (AK) of Upper Extremities.’ The study aims to assess the efficacy and safety of a reformulated version of Levulan Kerastick combined with photodynamic therapy for treating actinic keratosis on the upper extremities. This research is crucial as it addresses a common precancerous skin condition, potentially offering a more effective treatment option.
The intervention being tested is the Reformulated Levulan Kerastick containing aminolevulinic acid hydrochloride (ALA HCl) at 20%, used in conjunction with a Blue Light Photodynamic Therapy Illuminator device, BLU-U® model 4170E. This combination is designed to treat actinic keratosis by targeting and clearing lesions through a photodynamic process.
The study is designed as a Phase 3, randomized, multi-center, evaluator-blind, vehicle-controlled trial. Participants are randomly assigned to receive either the active treatment or a placebo, with both groups undergoing blue light exposure. The primary goal is treatment, with a focus on achieving complete clearance of lesions by Week 12. The study employs a triple-masking approach to ensure unbiased results, with participants, investigators, and outcomes assessors blinded to treatment assignments.
The study is set to begin on August 20, 2025, with the primary completion date yet to be announced. The last update was also on August 20, 2025, indicating the study is in the preparatory phase. These dates are crucial as they mark the timeline for potential advancements in treatment options for actinic keratosis.
From a market perspective, this study could positively impact Sun Pharmaceutical’s stock performance by potentially introducing a new, effective treatment for actinic keratosis, a condition with a significant patient population. This could enhance investor sentiment and position Sun Pharmaceutical favorably against competitors in the dermatological treatment market.
The study is ongoing, with further details available on the ClinicalTrials portal.